Healthcare Industry News: Precision Therapeutics
News Release - January 24, 2012
Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer CarePITTSBURGH, Jan. 24, 2012 -- (Healthcare Sales & Marketing Network) -- Precision Therapeutics, Inc. has recently expanded their BioSpeciFx® product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test. By utilizing BioSpeciFx® results in combination with Precision Therapeutics' ChemoFx® in vitro drug response marker, physicians will receive both molecular and live-cell drug response information about a patient's tumor. Through the integration of these two tests, physicians can create a Comprehensive Tumor Profile, allowing them to more completely define their patient's cancer. In an effort to personalize treatment selection even further, BioSpeciFx® and ChemoFx® tests give physicians the ability to choose from suggested tumor-specific panels or to customize a report for each patient.
"The decision to add new biomarker tests to Precision Therapeutics' Comprehensive Tumor Profile was a direct result of market trends and customer requests," says Sean McDonald, CEO. "Precision is committed to producing multiple products that help physicians make difficult clinical decisions throughout the cancer care continuum. We are in the process of developing several additional tools to help us adhere to our mission of improving the odds of survival and the quality of life for cancer patients."
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer through a portfolio of multi-platform tests for cancer treatment in multiple tumor types.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, over 77,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.
For more information, visit www.precisiontherapeutics.com or www.chemofx.com.
Source: Precision Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.